Stefan Roos presents at Apotekarsociteten seminar of live bacteria as pharmaceuticals November 27, online
The Scale-up Investor Ready Program prepares entrepreneurs for the transatlantic investor market and increases the chances of successful financing.
Ilya Pharma will present new data in antimicrobial resistance (AMR) and the bacterial killing activity of ILP100 on multi-drug-resitant (MDR) pathogenic bacteria isolated from War victims in Ukraine.
The work is funded by Ilya Pharma AB, Bio-X grant from STUNS in Uppsala and the Knut and Alice Wallenberg Foundation.
The company is insourcing business administration.
CXCL12-expressing Limosilactobacillus reuteri has clinically relevant antimicrobial effects of multidrug-resistant bacteria isolated from wounds of war victims in Ukraine Presented by Dr Andreas Fasth Poster ID 939